Engineering and stable production of recombinant IgE for cancer immunotherapy and AllergoOncology - 05/04/18
Doi : 10.1016/j.jaci.2017.12.986
Silvia Crescioli, PhD a, b, ∗, Giulia Chiaruttini, PhD a, ∗, Silvia Mele, PhD a, Kristina M. Ilieva, MRes a, c, Giulia Pellizzari, MSc a, Daniel I.R. Spencer, PhD d, Richard A. Gardner, PhD d, Katie E. Lacy, MD, PhD a, James F. Spicer, MD, PhD e, Andrew N.J. Tutt, PhD c, f, Gerd K. Wagner, PhD g, Sophia N. Karagiannis, PhD a, b, c 
a St John's Institute of Dermatology, School of Basic & Medical Biosciences, King's College London, London, United Kingdom
b NIHR Biomedical Research Centre at Guy's and St Thomas's Hospitals and King's College London, London, United Kingdom
c Breast Cancer Now Unit, School of Cancer & Pharmaceutical Sciences, King's College London, Guy's Cancer Centre, London, United Kingdom
d Ludger, Culham Science Centre, Abingdon, United Kingdom
e School of Cancer & Pharmaceutical Sciences, King's College London, Guy's Hospital, London, United Kingdom
f Breast Cancer Now Toby Robins Research Centre, Institute of Cancer Research, London, United Kingdom
g Department of Chemistry, Faculty of Natural & Mathematical Sciences, King's College London, London, United Kingdom
| Supported by the National Institute for Health Research (NIHR) BRC based at Guy's and St Thomas' NHS Foundation Trust and King's College London (IS-BRC-1215-20006). The views expressed are those of the author(s) and not necessarily those of the National Health Service, the National Institute for Health Research, or the Department of Health. The authors acknowledge support by the Medical Research Council (MR/L023091/1); Breast Cancer Now (147), working in partnership with Walk the Walk; the British Skin Foundation (S633); Dermatrust; Guy's and St Thomas's Charity Melanoma Special Fund; Cancer Research UK (C30122/A11527; C30122/A157745); the Academy of Medical Sciences; CR UK/EPSRC/MRC/NIHR KCL/UCL Comprehensive Cancer Imaging Centre (C1519/A10331); CR UK/NIHR in England/DoH for Scotland, Wales, and Northern Ireland Experimental Cancer Medicine Centre (C10355/A15587); and the BBSRC IBCarb Network (Proof-of-Concept award IBCarb-PoC-0616-040). |
|
| Disclosure of potential conflict of interest: S. Crescioli reports a grant from the National Institute for Health Research (NIHR) Biomedical Research Center (BRC). G. Chiaruttini reports a grant from the Medical Research Council (MRC). S. Mele reports a grant from the MRC. K. M. Ilieva received grant support for travel to meetings for the study or other purposes from Breast Cancer Now. G. Pellizzari reports grants from the Cancer Research UK (CRUK) and MRC. D. I. R. Spencer reports employment and other support from Ludger and has grants/grants pending from the European Union (EU) and UK Innovate grants. R. A. Gardner reports employment and other support from Ludger and has grants/grants pending from EU and UK Innovate grants. K. E. Lacy reports employment as a consultant dermatologist at Guys and St Thomas' Hospital and the London Bridge Hospital. J. F. Spicer reports grants/grants pending from Cancer Research UK and stock/stock options from IGEM Therapeutics. A. N. J. Tutt reports a grant from Breast Cancer Now and consultancy fees from Merck Serono, AstraZeneca, Eisai, and Celgene; payment for lectures, including service on speakers' bureaus, for AstraZeneca; royalties from the Institute of Cancer Research; payment for development of educational presentations from PRIME and PER; and travel/accommodations/meeting expenses unrelated to activities listed from Celgene, Breast Cancer Now, and the Breast International Group. G. K. Wagner reports a grant from the BBSRC. S. N. Karagiannis reports grants from the NIHR Biomedical Research Centre at Guy's and St Thomas's Hospitals National Health Service Trust and King's College London, the MRC, Breast Cancer Now, CRUK/NIHR in England/DoF for Scotland, Wales, and Northern Ireland Experimental Cancer Medicine Centre, Cancer Research UK, Biotechnology and Biological Sciences Research Council (BBSRC), British Skin Foundation, and Guy's and St Thomas's Charity; consultancy from IGEM Therapeutics; grants/grants pending from the Academy of Medical Sciences; patents (planned, pending, or issued) from IgE for cancer; and stock/stock options from IGEM Therapeutics. |
© 2018
The Authors. Publié par Elsevier Masson SAS. Tous droits réservés.
Vol 141 - N° 4
P. 1519 - avril 2018 Retour au numéro
Article précédent
- Asthma, COPD, and overlap in a national cohort: ACO on a gradient
- Arnaud Bourdin, Carey M. Suehs, Gregory Marin, Isabelle Vachier, Eric Matzner-Lober, Pascal Chanez, Nicolas Molinari, COBRA Consortium ?
- Serum biomarker profiles suggest that atopic dermatitis is a systemic disease
- Judith L. Thijs, Ian Strickland, Carla A.F.M. Bruijnzeel-Koomen, Stefan Nierkens, Barbara Giovannone, Edward F. Knol, Eszter Csomor, Bret R. Sellman, Tomas Mustelin, Matthew A. Sleeman, Marjolein S. de Bruin-Weller, Athula Herath, Julia Drylewicz, Richard D. May, DirkJan Hijnen
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?